National Preparedness

BARDA Signs a Multi-Year Agreement with Regeneron for its REGN-EB3 for National Preparedness

  • by

Shots: Regeneron will be responsible to deliver treatment doses for six years post-approval of product from the FDA, will receive compensation of ~$10M & average of $67M/year in 2021 and each for the next five years (2022-2026) respectively In 2019, the PALM trial evaluated REGN-EB3… Read More »BARDA Signs a Multi-Year Agreement with Regeneron for its REGN-EB3 for National Preparedness